Drilldown: Medicines
Medicines > classes 
:
Dissociative or
Opioid or
[[:Category:Antisecretory_agents|Gastric acid suppressant]]
:
Dissociative or
Opioid or
[[:Category:Antisecretory_agents|Gastric acid suppressant]] Use the filters below to narrow your results.
generic:
brand:
None (29) ·
(multiple, generic dominant) (1) ·
Alfenta (1) ·
Darvon (1) ·
Demerol (1) ·
Dilaudid (1) ·
Duragesic (1) ·
DXM (1) ·
DXO (1) ·
Heroin (1) ·
Krokodil (1) ·
Nexium, Nexium 24HR (OTC) (1) ·
Nubain (1) ·
Nucynta (1) ·
O-DSMT (1) ·
Opana (1) ·
Pepcid, Pepcid AC, Pepcid Complete (1) ·
Prilosec, Losec, Zegerid (1) ·
Protonix (1) ·
Spravato (1) ·
Stablon (1) ·
Stadol (1) ·
Sufenta (1) ·
Talwin (1) ·
Ultiva (1) ·
Vicodin (1)
classes: (Click arrow to add another value)
mechanism:
uses:
None (48) ·
Mild to moderate pain; cough suppression (low-dose). (1) ·
Treatment-resistant depression (TRD) in adults, as adjunct to oral antidepressant (FDA-approved March 2019). Depressive symptoms in adults with MDD with acute suicidal ideation or behavior (FDA-approved Aug 2020). (1) ·
'"`UNIQ--vote-000000DA-QINU`"', '"`UNIQ--vote-000000DB-QINU`"', '"`UNIQ--vote-000000DC-QINU`"', '"`UNIQ--vote-000000DD-QINU`"' (1) ·
'"`UNIQ--vote-00000119-QINU`"', '"`UNIQ--vote-0000011A-QINU`"', '"`UNIQ--vote-0000011B-QINU`"', '"`UNIQ--vote-0000011C-QINU`"' (1) ·
'"`UNIQ--vote-00000257-QINU`"', '"`UNIQ--vote-00000258-QINU`"', '"`UNIQ--vote-00000259-QINU`"', '"`UNIQ--vote-0000025A-QINU`"' (1) ·
'"`UNIQ--vote-000008E3-QINU`"', '"`UNIQ--vote-000008E4-QINU`"', '"`UNIQ--vote-000008E5-QINU`"', '"`UNIQ--vote-000008E6-QINU`"', '"`UNIQ--vote-000008E7-QINU`"' (1)
starting dose:
None (48) ·
20 mg PO once daily 30-60 minutes before breakfast (1) ·
20 mg PO twice daily, or 40 mg at bedtime (1) ·
20-40 mg PO once daily, 30-60 minutes before breakfast (1) ·
40 mg PO or IV once daily (1) ·
Adult: 15–60 mg every 4 hours as needed. (1) ·
Induction (TRD): 56 mg intranasal twice weekly × 4 weeks. Maintenance: 56-84 mg once weekly × 4 weeks, then 56-84 mg every 1-2 weeks. For acute suicidality: 84 mg twice weekly × 4 weeks. Administered under medical supervision in REMS-certified site. (1)
preparations:
None (48) ·
10 mg, 20 mg, 40 mg tablets; chewables; 40 mg/5 mL oral suspension; 10 mg/mL IV (1) ·
10, 20, 40 mg delayed-release capsules and tablets; 2 mg/mL oral suspension; immediate-release combo with sodium bicarbonate (Zegerid) (1) ·
20 mg, 40 mg delayed-release tablets; 40 mg IV vial; oral suspension 40 mg/packet (1) ·
20, 40 mg delayed-release capsules; 2.5, 5, 10, 20, 40 mg oral suspension packets; 20, 40 mg IV (1) ·
28 mg/device (each dose uses 2 devices) (1) ·
Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)
fda max:
routes:
onset:
None (48) ·
1 hour PO; minutes IV (1) ·
2-3 hours per dose; full acid suppression after 3-5 days (1) ·
30–60 min (PO) (1) ·
Acid suppression within hours; full effect after 3-5 days of dosing (1) ·
Symptom relief 1-4 days; full acid suppression after 3-5 days of dosing (1) ·
Within hours of first administration (1)
duration:
None (48) ·
24+ hours (irreversible enzyme binding) (1) ·
24-72 hours per dose (irreversible enzyme binding) (1) ·
24-72 hours per dose (irreversible enzyme binding; effect outlasts plasma exposure) (1) ·
4–6 hours (1) ·
6-12 hours (1) ·
Acute effect ~24 hours; cumulative effect builds with repeated dosing (1)
halflife:
None (48) ·
0.5-1.5 hours (plasma); pharmacodynamic effect persists 24+ hours'"`UNIQ--ref-000000DE-QINU`"' (1) ·
2.5-3.5 hours; longer in renal impairment'"`UNIQ--ref-0000025B-QINU`"' (1) ·
2.5–3 hours (1) ·
~1 hour (plasma); pharmacodynamic effect persists 24+ hours'"`UNIQ--ref-0000011D-QINU`"' (1) ·
~1.5 hours (plasma); pharmacodynamic effect 24+ hours via target turnover'"`UNIQ--ref-000008E8-QINU`"' (1) ·
~7-12 hours (1)
bioavailability:
None (48) ·
30-40% (oral; increases with repeated dosing as gastric pH rises)'"`UNIQ--ref-000000DF-QINU`"' (1) ·
40-45% (oral; not significantly affected by food)'"`UNIQ--ref-0000025C-QINU`"' (1) ·
~48% intranasal (1) ·
~50% (variable, CYP2D6-dependent for analgesic effect). (1) ·
~64-90% (oral; increases at higher doses and with multi-day dosing)'"`UNIQ--ref-000008E9-QINU`"' (1) ·
~77% (oral; not affected by food or antacids)'"`UNIQ--ref-0000011E-QINU`"' (1)
pregnancy:
None (48) ·
Avoid; may cause fetal harm (1) ·
Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) ·
Generally considered safe; widely used in obstetric reflux.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Generally considered safe; widely used. Cleared in lactation at low levels.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Widely used in obstetric reflux; reassuring data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Widely used in pregnancy; meta-analyses do not show increased malformation risk.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
legal:
None (48) ·
OTC (10-20 mg) and [[USLegal:Prescription only|Rx-only]] (higher doses) in US (1) ·
OTC (20 mg) and [[USLegal:Prescription only|Rx-only]] (higher doses) in US (1) ·
OTC (20 mg, 14-day course) and [[USLegal:Prescription only|Rx-only]] (higher and longer durations) in US (1) ·
Rx, Schedule III (US). REMS program required. (1) ·
US Schedule II (single-entity); Schedule III–V (combination products by content). (1) ·
[[USLegal:Prescription only|Rx-only]] in US (1)
Showing below up to 54 results in range #1 to #54.